Three target populations | Description | Reference/First author [Ref.] |
All people with TB signs and symptoms | ||
Shortened title used in figures | TB-SS | |
Number | Assume 10 people with TB signs and symptoms per one smear-positive TB case notified in 2011 | 2011 Global TB Report [1] |
Conventional practice for diagnosis | Two smears and one radiograph for those smear-negative (S-X) | WHO guidelines [22] |
Additional tests for South Africa, Russia, Estonia and Kazakhstan | One culture test (S-X-C) | |
Xpert MTB/RIF | One test per person | Xpert MTB/RIF rapid implementation guidance [21] |
DST (and culture) follow-on test when using Xpert MTB/RIF (confirmatory test) | One culture test followed by one DST for two firstline drugs (rifampicin and isoniazid; solid or liquid) per patient with rifampicin- resistant result with Xpert MTB/RIF | Xpert MTB/RIF rapid implementation guidance [21] |
Proportion of Xpert tested patients with rifampicin-resistant positive result | Proportion of rifampicin resistance (where data are available); and estimated proportion of new TB cases that have MDR-TB (if data on rifampicin resistance are not available) | Zignol [23] and 2011 Global TB Report [1] |
HIV-positive individuals (or HIV unknown in high HIV settings) with TB signs and symptoms | ||
Shortened title used in figures | TB-SS, HIV positive | |
Number | Proportion of tested TB patients HIV positive multiplied by all people with TB signs and symptoms | 2011 Global TB Report [1] |
Conventional practice for diagnosis | Two smears, one radiograph and one culture (S-X-C) | WHO guidelines for TB/HIV [4] |
Xpert MTB/RIF | One test per suspect | Xpert MTB/RIF rapid implementation guidance [21] |
DST (and culture) follow-on test when using Xpert MTB/RIF (confirmatory test) | One culture test followed by one DST for two firstline drugs (rifampicin and isoniazid; solid or liquid) per patient with rifampicin-resistant result with Xpert MTB/RIF | Xpert MTB/RIF rapid implementation guidance [21] |
Proportion of Xpert tested patients with rifampicin-resistant positive result | Proportion of rifampicin resistance (where data are available); and estimated proportion of new TB cases that have MDR-TB (if data on rifampicin resistance are not available) | Zignol [23] and 2011 Global TB Report [1] |
Individuals at risk of having MDR-TB, diagnosed with TB or with TB signs and symptoms | ||
Shortened title used in figures | MDR-TB, high-risk | |
Number | 20% of all new TB cases + 100% TB retreatment cases | 2011 Global TB Report [1] |
Conventional practice for diagnosis | One culture test + one DST for two drugs (rifampicin and isoniazid; solid or liquid media) | WHO guidelines for MDR-TB [12] |
Xpert MTB/RIF | One test per person | Xpert MTB/RIF rapid implementation guidance [21] |
DST (and culture) follow-on test when using Xpert MTB/RIF (confirmatory test) | One culture test followed by one DST for two firstline drugs (rifampicin and isoniazid; solid or liquid) per patient with rifampicin-resistant result with Xpert MTB/RIF | Xpert MTB/RIF rapid implementation guidance [21] |
Proportion of Xpert tested patients with rifampicin resistance result | Proportion of rifampicin resistance (where data are available); and estimated proportion of new TB cases that have MDR-TB (if data on rifampicin resistance are not available) | Zignol [23] and 2011 Global TB Report [1] |
TB: tuberculosis; S: smear microscopy; X: radiograph; C: culture; DST: drug susceptibility testing; MDR-TB: multidrug-resistant tuberculosis.